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The platelet aggregation is an important process, which is critical for the hemostatic plug formation and throm-
bosis. Recent studies have shown that the platelet aggregation is more complex and dynamic than it was previous-
ly thought. There are several mechanisms that can initiate the platelet aggregation and each of them operates un-
der specific conditions in vivo. At the same time, the influence of certain plasma proteins on this process should
be considered. This review intends to summarize the recent data concerning the adhesive molecules and their re-
ceptors, which provide the platelet aggregation under different conditions.
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Introduction. Platelets play an important role in hemo- 
stasis, thrombosis, wound healing, atherosclerosis, in-
flammation, immunity and tumor metastasis [1–3]. How-
ever, their main physiological function is the forming of
hemostatic thrombi to prevent blood loss. The biochemi-
cal and cellular processes responsible for this function
can be divided into four steps: adhesion, activation, sec-
retion and aggregation. It is known that the platelets are 
exposed to a broad range of hemodynamic conditions in 
vivo, ranging from low-flow situations in venules and
large veins (< 500 s–1) to stenosed arteries with extre-
mely high shear rates (till 40,000 s–1) [4]. Here we have
considered the peculiarities of above mentioned steps un-
der different hemodynamic conditions.
Platelet adhesion. The platelet adhesion is the pro- 
cess, through which the platelets establish contacts with
the extracellular matrix. Under normal conditions the
endothelial cells form a surface resistant to the adhesion
of circulating platelets. The primary event, which leads
to the platelet adhesion, is the damage of vessel wall. As
the platelets are not able to distinguish between the trau-
matic vessel damage and the diseased arterial walls the
same life saving reaction can become potentially dange-
rous in case of atherosclerosis. When the endothelial
cell layer of a vessel wall is damaged the components of
subendothelial matrix, primarily collagen and von Wil- 
lebrand factor (vWF) will be exposed to the blood. The
initial tethering of the platelets to the extracellular mat-
rix (ECM) is mediated by the interaction between the
platelet receptor glycoprotein GP Ib-IX-V and vWF
bound to collagen [5]. It is noted that GP Ib can initiate
the adhesion by interacting with other ligands. The most
probable candidate for this role is thrombospondin-1 [6].
Using traditional aggregometry methods we have a
model with low, nonlaminar shear conditions. To study 
the vWF/GP Ib-IX-V interaction many investigators
traditionally use ristocetin, a bacterial-derived antibio-
tic from Nocardia lurida. The vWF deficiency is accom- 
panied with the absence or low level of the ristocetin-
induced aggregation whereas the ADP- or collagen-in-
duced aggregation is normal. The absence of ristocetin- 
induced aggregation can be also a result of the loss of
GP Ib from the platelet surface. In this case the platelets 
of enormous size are determined in blood [7].
The binding site for GP Ib in the vWF structure is the 
A1 domain. In the vWF multimers, which circulate in
blood, this domain is not accessible for interacting with 
the platelets. Binding to collagen under shear stress con-
ditions leads to the conformational changes in the vWF
molecule [8] and provides the platelet interaction with en- 
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dothelium collagen. This interaction is not strong enough
to mediate stable adhesion but maintains the platelets in 
close contact with the surface. At this period the platelets
establish additional contacts with collagen through the
Ig-superfamily receptor, GP VI. This receptor is associa-
ted with the Fc-receptor, which bears the immunorecep- 
tor tyrosine-based activation motifs (ITAM) for signal
transduction. While GP VI binds collagen with low affi-
nity, it triggers the shift of platelet integrins (α2β1 and
IIbIIIa) to a high-affinity state. The main steps of this
process are shown in Fig. 1. The integrin collagen re-
ceptor α2β1 binds to collagen and facilitates the engage-
ment of GP VI [9].
Platelet activation. When GP VI is crosslinked and
clustered by collagen, this leads to the activation of the
Src tyrosine kinases (Fyn and Lyn) bound to the cyto-
plasmatic tail of GP VI. The ITAMs present on the FcR
γ-chain are phosphorylated by Fyn and Lyn, next al-
lowing for the involvement of the tyrosine kinase Syk.
Syk in turn induces a signaling cascade resulting in the
activation of phospholipase Cγ (PlCγ). This enzyme
hydrolyzes phosphatidylinositol 4,5 bisphosphate to
produce inositol trisphosphate (IP3) and diacylglycerol
(DAG), which activate calcium mobilization and pro-
tein kinase C, respectively. Increased calcium levels
lead to the activation of the  Ca2+ and DAG-regulated
guanine nucleotide exchange factor I (Cal DAG-GEFI),
which itself activates Rap 1b, a small GTP binding pro-
tein. The interaction of activated Rap 1b with the Rap
1-interacting adaptor molecule (RIAM) and talin re-
sults in the formation of an «activation complex». The
interaction of talin with Rap1b and RIAM leads to the
unmasking of the integrin-binding site on talin. Talin
hence binds to the integrin β3 tail, which leads to the dis-
ruption of the clasp between α and β subunits of IIbIIIa
integrin. This separation of the integrin cytosolic re-
gion is transmitted to the extracellular domains which
change from a bent to an extended conformation. Re-
cently it has been shown that kindlin is also an important
mediator of the integrin activation [10]. However, the
interplay between talin and kindlin in the integrin acti-
vation still needs to be elucidated. After the activation
IIbIIIa integrin acquires abilities to bind fibrinogen and
other adhesive ligands [11]. The numerous works provi-
de evidence that IIbIIIa the integrin activation occur-
ring in response to the external signals results in inter-
nal changes [12–14]. During the activation, the cytoskele-
tal reorganization takes place and this event is conside-
red to be one of the earliest hallmark of the platelet acti-
vation. In the activated platelets, the rapid F-actin polyme- 
rization and formation of complex between the membra-
ne cortex cytoskeleton and the cytoplasmic filaments are
observed. Remodeling of the actin cytoskeleton is neces-
sary for the blood coagulation because the actin fila-
ments in the activated platelets mediate such crucial pro-
cesses as the adherence to extracellular matrix and to
other cells, extension of filopodia and lamellipodia, ma-
intenance of the platelet morphology, contraction of the
inner central cytoplasm facilitating the expulsion of gra-
nule content such as growth factors and vasoactive sub-
stances, ultimately contraction of the whole cell, which
is required for the clot retraction [15]. Thus, the integrins
provide a transmembrane linkage between the cytoskele- 
ton and the extracellular matrix. It has been revealed that
the cytoskeleton plays a critical role in the two-way com- 
munication across the integrins: binding of extracellular
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adhesive molecule to the integrin regulates the organiza-
tion of cytoskeleton, in turn the cytoskeleton regulates
the adhesive properties of the integrin [16,17]. It is well-
documented that cytochalasins, which disrupt the actin
fibers, cause the integrin to dissociate from its adhesive
ligand, and the cytochalasin-treated platelets fail to ag-
gregate even in the presence of agonists [18]. Besides,
the activated platelets, as well as several types of cancer
and normal cells, are able to expose actin on the surface
of their plasma membrane. It is suggested that the surface 
actin may play a role of specific site for binding some
molecules regulating the platelet adhesion and aggrega-
tion [19].
Speaking about the platelet activation, we have to pay
attention to the most potent platelet activator, throm-
bin. Small amounts of thrombin are formed on the sur-
face of a tissue factor presenting cell (fibroblast or acti-
vated monocyte or activated endothelial cell, respecti-
vely). These amounts of thrombin are not able to pro-
duce a stable fibrin clot, but are enough to activate the
platelets. Thrombin binds the protease-activated recep- 
tors (PAR-1 and PAR-4) on the platelet surface. The fol-
lowing signaling mechanism includes the activation of
phospholipase Cβ (see Fig. 1). Thrombin also binds
GP-Ib, which has been proposed to enhance the speci-
ficity of thrombin cleavage of PAR-1 [20]. 
Platelet secretion. The activated platelets release
several granule components, which modulate functions 
of the interacting platelets. The dense bodies of the pla-
telets contain secondary agonists like ADP and seroto-
nin. There are two important ADP receptors on the pla-
telet surface. The P2Y1-receptor modulates the calcium
mobilization and shape change [21]. The PY12-recep-
tor potentiates the platelet secretion and is involved in
the irreversible aggregation [22]. Serotonin binds to the 
Gq-coupled receptor and together with ADP amplifies
the platelet response. Additionally, serotonin may play
a specific role in the retention of fibrinogen and throm-
bospondin on the platelet surface [23]. The platelet ac-
tivation also results in the releasing of α-granule pro-
teins: adhesive molecules (vWF, thrombospondin, vit-
ronectin and fibronectin), mitogenic factors, coagula-
tion factors and protease inhibitors. P-selectin is exclu-
sively localized on the α-granule membrane of the res-
ting platelets. However, during the secretion it migrates 
on the platelet surface as a result of the fusion of α-gra-
nule membrane with the plasma membrane. This adhe-
sive protein mediates the platelet binding with
leukocytes [24].
Platelet aggregation. The main mechanism of the
platelet aggregation is thought to be realized through
the interaction of fibrinogen with integrin IIbIIIa [25].
However, other adhesive molecules, such as thrombo-
spondin, vWF, vitronectin and fibronectin are necessa-
ry to provide effective aggregation (see Fig. 2). It was
shown that fibrinogen, vWF and fibronectin have si-
milar binding affinities to the activated form of IIbIIIa
[26]. Under low shear conditions, fibrinogen is the do-
minant ligand of the platelet aggregation thanks to its
high molar ratio in plasma compared with other ligands.
In vivo studies on mice with a targeted deletion of vWF
or fibrinogen demonstrated that vWF plays a main role
in initiating aggregation under high shear with fibrino-
gen (and fibrin) playing a secondary role in stabilizing
the formed aggregates. The thrombus formation still oc-
curs in mice lacking both vWF and fibrinogen [27],
which suggests that other proteins (fibronectin, throm-
bospondin and vitronectin) may be able to mediate the
platelet adhesion and aggregation. In vitro studies show-
ed that the second wave of the thrombin-induced aggre- 
gation of gel-filtered the platelets was abolished at a low
concentration of thrombin in the vitronectin-deficient
platelets [28]. Contrary to the released platelet granule
vitronectin, which enhances the platelet aggregation, the
plasma vitronectin inhibits the platelet aggregation. The
role of vWF in the platelet aggregation is also signifi-
cant. In high shear environments the platelets are the
first linked by vWF bridges via the GP Ib/V/IX comp-
lex. This interaction leads to the activation of the inte-
grin IIbIIIa and in turn to the stabilization of the vWF-
mediated platelet aggregates [29]. The recent studies on
mice, which express low levels of the plasma and pla-
telet fibronectin have confirmed the involvement of this 
protein in the platelet aggregation [30]. Fibronectin is
able to bind fibrinogen and thrombospondin, thus in-
creasing the stability of the platelet-platelet interac-
tions [31]. Similar to vWF, fibronectin undergoes con-
formational changes in response to the mechanical stress
[32]. That can explain the role of fibronectin in promo-
ting of thrombus formation under high shear. Notably, a 
combination of ligands (such as vWF/fibrinogen or fib-
ronectin/fibrin) is far more reactive to the platelets than
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in isolation. It can be important because the elevated
plasma levels of vWF, fibrinogen, and possibly fibro-
nectin independently increase a risk of the atherothrom-
botic complications [33].
There are some interesting data about the influence
of some plasma proteins on the platelet aggregation.
Among them, plasminogen, a 92-kDa single-chain zy-
mogen, is essential for efficient fibrinolysis and facilita-
tes cell migration. Plasminogen can be considered as an 
adhesive ligand for the integrins found on the surface of
the platelets and leucocytes [34]. It is known that plas-
minogen binds to the platelet surface, and the activated
platelets possess an increased affinity to plasminogen
[35]. Moreover, for the hemodialysis patients the corre- 
lation between plasminogen level in plasma and the pla-
telet aggregation was observed [36]. Recently, we have 
studied the effect of Lys- and Glu-plasminogen on the
human platelet aggregation [37, 38]. Under physiologi- 
cal conditions, Lys-plasminogen and Lys-plasmin are
not present in circulating blood [39]. However, in the
patients undergoing thrombolytic therapy using the tis- 
sue plasminogen activator, a low amount of Lys-plas-
minogen was detected [39]. We have shown that Lys-
plasminogen but not its Glu-form inhibits the thrombin-
and collagen-induced aggregation in the preparations
of washed human platelets. The level of aggregation in
both cases decreases at least by two times. It has been
found that ε-aminocaproic acid (1 mM) abolishes the
inhibitory effect of Lys-plasminogen that is compatible 
with the participation of lysine-binding sites of 1–5 krin- 
gles of the proenzyme in the inhibitory process. We ha-
ve shown that kringle 1–3, kringle 5 and kringle 4 act as 
competitors of the proenzyme molecule when they we-
re incubated with the washed platelets and exogeneous
Lys-plasminogen. It is quite possible that Lys-plasmi-
nogen binds some proteins, which are released during
the α-granule secretion and stay bound with the platelet 
membrane (such as fibrinogen, thrombospondin, vitro-
nectin etc.). So, exogeneous Lys-plasminogen could
impede the formation of platelet aggregates.
The relationship between the adhesive ligands and
the platelet receptors can also be important considering
the side effects of some anticoagulants. It is well known,
that the heparin preparations influence the platelet ag-
gregation. It was shown, that heparin induces a slight
increase of the platelet aggregation in the platelet rich
plasma preparations meanwhile the significant inhibito-
ry activity is observed when heparin was added to the
washed platelets [40]. The most pronounced inhibitory
effect was in case of the ristocetin-induced aggregation
however with other agonists (thrombin, epinephrine and 
ADP) it also took place. It was found that heparin is ab-
le to associate directly with the major platelet integrin
IIbIIIa triggering a signaling cascade that leads to the
activation of phosphatidyl-inositol-3-kinase [41]. On
the other hand, IIbIIIa is not the only side for heparin
because the latter can bind numerous platelet protein
compounds of the platelet α-granule, including vWF,
13
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Fig. 2. The scheme of platelet aggre-
gation: vWF – von Willebrand factor; 
Fg – fibrinogen; Fc – fibronectin
fibronectin, thrombospondin and vitronectin [42–45].
Taking into consideration all the above mentioned data,
we can make the following suggestion. In the plasma
preparations where fibrinogen is abundant, an influen-
ce of other adhesive ligands is not crucial, so heparin
shows its stimulating effect. In case of the washed pla-
telets the efficiency of platelet aggregation depends on
the binding of α-granule proteins with the platelet re-
ceptors (IIbIIIa and GP I/IX/V). So, heparin can bind
the adhesive ligands and impede the platelet aggrega-
tion. Probably, the interaction GP Ib-vWF is the main
site of the heparin influence. 
Perspectives. In the recent years, both in vitro and
in vivo studies on the structure and function of the pla-
telet adhesion molecules have provided new insights in-
to the platelets interaction with the injured vessel wall
and with each other under different conditions. The ob-
tained results can be important not only for a better un-
derstanding of the molecular mechanisms underlying
thrombosis, but also may reveal new therapeutic targets 
for the treatment of disorders such as the inflammatory
diseases, atherosclerosis, and cancer. 
Íîâ³ àñ ïåê òè àã ðå ãàö³¿ òðîì áî öèò³â
ß. Ì. Ðîêà-Ìîéÿ, Â. Ë. Á³ëîóñ,  Ä. Ä. Æåð íîñºêîâ, Ò. Â. Ãðè íåí êî 
Ðå çþ ìå
Â³äîìî, ùî àã ðå ãàö³ÿ òðîì áî öèò³â – öå âàæ ëè âèé ïðî öåñ, ÿêèé ëå -
æèòü â îñíîâ³ óòâî ðåí íÿ ãå ìîñ òà òè÷ íî¿ ïðî áêè òà ôîð ìó âàí íÿ
òðîì áà. Îäíàê îñòàíí³ äîñë³äæåí íÿ ïî êà çà ëè, ùî òðîì áî öè òàð-
íà àã ðå ãàö³ÿ º çíà÷ íî ñêëàäí³øèì ³ äè íàì³÷í³øèì ïðî öå ñîì, í³æ
ââà æà ëè ðàí³øå. ²ñíóº äåê³ëüêà ìå õàí³çì³â, ÿê³ ³í³ö³þþòü àã ðå -
ãàö³þ òðîì áî öèò³â, ³ êî æåí ³ç íèõ ðåàë³çóºòüñÿ çà ïåâ íèõ óìîâ in
vivo. Ó òîé æå ÷àñ íå îáõ³äíî âðà õî âó âà òè âïëèâ íà öåé ïðî öåñ
îêðå ìèõ á³ëê³â ïëàç ìè êðîâ³. Ìåòà äà íî ãî îãëÿ äó – óçà ãàëü íè òè
ñó ÷àñí³ äàí³, ïðè ñâÿ ÷åí³ àä ãå çèâ íèì ìî ëå êó ëàì òà ¿õí³ì ðå öåï òî -
ðàì, ÿê³ çà áåç ïå ÷ó þòü òðîì áî öè òàð íó àã ðå ãàö³þ çà ð³çíèõ óìîâ.
Êëþ ÷îâ³ ñëî âà: àã ðå ãàö³ÿ òðîì áî öèò³â, àä ãå çèâí³ ìî ëå êó ëè.
Íî âûå àñ ïåê òû àã ðå ãà öèè òðîì áî öè òîâ
ß. Ì. Ðîêà-Ìîéÿ, Â. Ë. Áè ëî óñ, Ä. Ä. Æåð íî ñå êîâ, Ò. Â. Ãðè íåí êî 
Ðå çþ ìå
Èçâåñòíî, ÷òî àãðå ãà öèÿ òðîì áî öè òîâ ÿâ ëÿ åò ñÿ âàæ íûì ïðî -
öåñ ñîì, ëå æà ùèì â îñíî âå îá ðà çî âà íèÿ ãå ìîñ òà òè ÷åñ êîé ïðî áêè
è ôîð ìè ðî âà íèÿ òðîì áà. Îäíà êî íåäàâ íèå èñ ñëå äî âà íèÿ ïî êà çà -
ëè, ÷òî òðîì áî öè òàð íàÿ àã ðå ãà öèÿ – ýòî áî ëåå ñëîæ íûé è äè íà -
ìè÷ íûé ïðî öåññ, ÷åì ñ÷è òà ëè  ðà íåå. Ñó ùåñ òâó åò íå ñêîëü êî ìå-
õà íèç ìîâ, èíè öè è ðóþùèõ àã ðå ãà öèþ òðîì áî öè òîâ, è êàæ äûé èç
íèõ ðå à ëè çó åò ñÿ ïðè îïðå äå ëåí íûõ óñëî âè ÿõ in vivo. Â òî æå âðå -
ìÿ íå îá õî äè ìî ó÷è òû âàòü âëè ÿ íèå íà ýòîò ïðî öåññ îòäåëüíûõ
áåë êîâ ïëàç ìû êðî âè. Öåëü íà ñòî ÿ ùå ãî îá çî ðà – îá îá ùèòü ñî âðå -
ìåí íûå äàí íûå, ïî ñâÿ ùåí íûå àä ãå çèâ íûì ìî ëå êó ëàì è èõ ðå öåï -
òî ðàì, îá åñ ïå ÷è âàþùèì òðîì áî öè òàð íóþ àã ðå ãà öèþ â ðàç ëè÷-
íûõ óñëî âè ÿõ.
Êëþ ÷å âûå ñëî âà: àã ðå ãà öèÿ òðîì áî öè òîâ, àä ãå çèâ íûå ìî ëå êó ëû.
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